HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

Biochemical Journal

Volumn 447, Issue 3, 2012, Pages 417-425

  Amin, Dhara N ^a   Sergina, Natalia ^a   Lim, Lionel ^a   Goga, Andrei ^a   Moasser, Mark M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ErbB3; Human epidermal growth factor receptor 2 (HER2); Human epidermal growth factor receptor 3 (HER3); Tumorigenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; MOLECULAR DYNAMICS; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; CELL MEMBRANE; DOWN-REGULATION; HUMANS; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84867281628     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20120724     Document Type: Article

References (45)

1. Bazley, L. A. and Gullick, W. J. (2005) The epidermal growth factor receptor family. Endocr. Relat. Cancer 12 (Suppl 1), S17-S27 (Pubitemid 41395411)
2. Torbett, N. E., Luna-Moran, A., Knight, Z. A., Houk, A., Moasser, M., Weiss, W., Shokat, K. M. and Stokoe, D. (2008) A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem. J. 415, 97-110
3. Moasser, M. M. (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469-6487
4. Sharma, S. V., Bell, D. W., Settleman, J. and Haber, D. A. (2007) Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181
5. Pedersen, M. W., Meltorn, M., Damstrup, L. and Poulsen, H. S. (2001) The type III epidermal growth factor receptor mutation. Ann. Oncol. 12, 745-760
6. Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A. and Samuels, Y. (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127-1132
7. Sierke, S. L., Cheng, K., Kim, H. H. and Koland, J. G. (1997) Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 322, 757-763 (Pubitemid 27135621)
8. Jura, N., Shan, Y., Cao, X., Shaw, D. E. and Kuriyan, J. (2009) Structural analysis of the catalytically inactive kinase domain of the human HER3 receptor. Proc. Nat. Acad. Sci. U.S.A. 106, 21608-21613
9. Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A. and Carraway, 3rd, K. L. (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Nat. Acad. Sci. U.S.A. 91, 8132-8136
10. Warren, C. M. and Landgraf, R. (2006) Signaling through ERBB receptors: multiple layers of diversity and control. Cell. Signalling 18, 923-933
11. Amin, D. N., Campbell, M. R. and Moasser, M. M. (2010) The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin. Cell Dev. Biol. 21, 944-950
12. Campbell, M. R., Amin, D. and Moasser, M. M. (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin. Cancer Res. 16, 1373-1383
13. Soltoff, S. P., Carraway, 3rd, K. L., Prigent, S. A., Gullick, W. G. and Cantley, L. C. (1994) ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14, 3550-3558 (Pubitemid 24160762)
14. Prigent, S. A. and Gullick, W. J. (1994) Identification of c-erbB-3 binding sites for phosphatidylinositol 3′ -kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13, 2831-2841
15. Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, 3rd, C. F. and Hynes, N. E. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Nat. Acad. Sci. U.S.A. 100, 8933-8938 (Pubitemid 36899201)
16. Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X. and Stern, H. M. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878-5887
17. Amin, D. N., Sergina, N., Ahuja, D., McMahon, M., Blair, J. A., Wang, D., Hann, B., Koch, K. M., Shokat, K. M. and Moasser, M. M. (2010) Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2, 16ra17
18. Engelman, J. A., Janne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E. and Cantley, L. C. (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Nat. Acad. Sci. U.S.A. 102, 3788-3793 (Pubitemid 40354690)
19. Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M. and Moasser, M. M. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (Pubitemid 46160912)
20. Anand, N. K., Blazey, C. M., Bowles, O. J., Bussenius, J., Canne Bannen, L., Chan, D. S., Chen, B., Co, E. W., Costanzo, S., Defina, S. C. et al. (2005) Preparation and structure activity of pyrazolo-pyrimidine derivatives as antitumor agents and kinase modulators. Patent number WO2005117909
21. Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M. and Knight, Z. A. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699
22. Zhu, C. H. and Domann, F. E. (2002) Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth. Breast Cancer Res. Treat. 71, 47-57
23. Mueller, K., Yang, Z.-Q., Haddad, R., Ethier, S. and Boerner, J. (2010) EGFR/Met association regulates EGFR TKI resistance in breast cancer. J. Mol. Signal. 5, 8
24. Liu, L., Shi, H., Liu, Y., Anderson, A., Peterson, J., Greger, J., Martin, A.-M. and Gilmer, T. M. (2011) Synergistic effects of foretinib with HER-Targeted agents in MET and HER1-or HER2-coactivated tumor cells. Mol. Cancer Ther. 10, 518-530
25. Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D., Sanchez, V., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W., McKinely, E. et al. (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Nat. Acad. Sci. U.S.A. 108, 5021-5026
26. Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J. and Rosen, N. (2011) Akt inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71
27. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R. et al. (2004) The TSC12 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213-223 (Pubitemid 38988774)
28. Werner, E. D., Lee, J., Hansen, L., Yuan, M. and Shoelson, S. E. (2004) Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J. Biol. Chem. 279, 35298-35305 (Pubitemid 39100527)
29. Shah, O. J., Wang, Z. and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650-1656 (Pubitemid 39239362)
30. Michell, B. J., Griffiths, J. E., Mitchelhill, K. I., Rodriguez-Crespo, I., Tiganis, T., Bozinovski, S., de Montellano, P. R., Kemp, B. E. and Pearson, R. B. (1999) The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 9, 845-848 (Pubitemid 29375190)
31. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. and Zeiher, A. M. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605
32. Fulton, D., Gratton, J. P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A. and Sessa, W. C. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399, 597-601
33. Morgan, A. and Burgoyne, R. D. (2004) Membrane traffic: controlling membrane fusion by modifying NSF. Curr. Biol. 14, R968-R970 (Pubitemid 39547950)
34. Hay, J. C. and Scheller, R. H. (1997) SNAREs and NSF in targeted membrane fusion. Curr. Opin. Cell Biol. 9, 505-512 (Pubitemid 27354759)
35. Matsushita, K., Morrell, C. N., Cambien, B., Yang, S. X., Yamakuchi, M., Bao, C., Hara, M. R., Quick, R. A., Cao, W., O'Rourke, B. et al. (2003) Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115, 139-150 (Pubitemid 37329578)
36. Sollner, T. H. and Sequeira, S. (2003) S-nitrosylation of NSF controls membrane trafficking. Cell 115, 127-129 (Pubitemid 37329573)
37. Gonzalez, E. and McGraw, T. E. (2006) Insulin signaling diverges into Akt-dependent and -independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Mol. Biol. Cell 17, 4484-4493 (Pubitemid 44522065)
38. Wang, Q., Somwar, R., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R. and Klip, A. (1999) Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol. Cell. Biol. 19, 4008-4018 (Pubitemid 29241975)
39. Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Di Fiore, P. P. and Kraus, M. H. (1995) Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10, 1813-1821
40. Chakrabarty, A., Sanchez, V., Kuba, M. G., Rinehart, C. and Arteaga, C. L. (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Nat. Acad. Sci. U.S.A. 109, 2718-2723
41. Krig, S. R., Miller, J. K., Frietze, S., Beckett, L. A., Neve, R. M., Farnham, P. J., Yaswen, P. I. and Sweeney, C. A. (2010) ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 29, 5500-5510
42. Iorio, M. V., Casalini, P., Piovan, C., Di Leva, G., Merlo, A., Triulzi, T., Ménard, S., Croce, C. M. and Tagliabue, E. (2009) microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69, 2195-2200
43. Scott, G. K., Goga, A., Bhaumik, D., Berger, C. E., Sullivan, C. S. and Benz, C. C. (2007) Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479-1486 (Pubitemid 47076526)
44. Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D. and Shokat, K. M. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e1000038
45. Funes, M., Miller, J. K., Lai, C., Carraway, 3rd, K. L. and Sweeney, C. (2006) The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J. Biol. Chem. 281, 19310-19319 (Pubitemid 44035436)